Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q3 2019 Earnings Conference Call - Final Transcript

Nov 12, 2019 • 08:00 am ET


Helius Medical Technologies, Inc. (NASDAQ:HSDT) Q3 2019 Earnings Conference Call - Final Transcript


Loading Event

Loading Transcript


Good morning, ladies and gentlemen, and welcome to the Third Quarter of Fiscal Year 2019 Earnings Conference Call for Helius Medical Technologies. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the company's website for replay shortly.

Before we began, I'd like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management, including statements regarding the potential FDA marketing authorization of the PoNS device, the success of the company's planned study, the future commercialization of the PoNS treatment, expected future clinical and regulatory time lines, the potential receipt of regulatory clearance of the PoNS device in the United States and projected financial results. These forward-looking statements involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including those identified in the Risk Factors section in our most recent annual report on Form 10-K filed with the SEC on March 14, 2019 and as well as those in the Form 10-Q for the third quarter ended September 30, 2019, which was filed with the SEC this morning. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. All statements made during this call are as of November 12, 2019. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.

I would now like to turn the call over to Mr. Phil Deschamps, Helius Medical's Chief Executive Officer. Please go ahead, sir.

Phil Deschamps

Thank you very much, operator. Welcome, everyone to Helius Medical's third quarter of 2019 earnings conference call. I'm joined on the call today this morning by Joyce LaViscount, our Chief Financial Officer and Chief Operating Officer and by Dr. Ryan Scott, who is the Clinic Director at Advantage 4 Athletes Training Center and therapy clinic in Markham, Ontario, one of the Canadian clinics that is authorized to provide PoNS treatment.

Let me provide you with a quick agenda for today's call. We'll begin today's call by having Dr. Scott provide you with his perspective on our PoNS treatment and share his experience of one of the initial patients that was treated at his clinic. Following his remarks, I'll provide a brief update on outcomes from the patients that have recently completed PoNS treatment across the Canadian clinics. And then I'll review our third quarter revenue results and discuss some of the important operational progress that we made during the quarter, including updates on our commercial activities in Canada and our US regulatory strategy. Joyce will discuss the third quarter financial results in detail and review our guidance for 2019, which we updated in our earnings press release this morning. I'll then provide a few closing thoughts before Joyce and I open the